C. diff. Spores and More

Join us as Dr. Dale Gerding, MD, an Infectious Disease specialist, researcher, professor, hospital epidemiologist, and one of the leading international experts on Clostridium diffiicle (C.diff.), will discuss his patented non-toxigenic Clostridium difficile (NTCD-M3) technology for the prevention and treatment of a C. diff. infection. Dr.Gerding currently owns patents and all rights to the development, manufacturing, regulatory, and clinical trial data for NTCD-M3. The lead pharmaceutical product, NTCD-M3, incorporating this technology has already completed Phase 1 & 2 Clinical Trials, has FDA Fast Track approval, is expected to be eligible for Breakthrough Therapy Designation by the FDA for a Phase 3 Clinical Trial, and to be eligible for Reference Product Exclusivity for 12 years for an approved biologics license application.

Listen in as our guest, Dr. Deverick J. Anderson, MD, Director, Duke Center for Antimicrobial Stewardship and Infection Prevention, Associate Professor of Medicine, Division of Infectious Diseases, discusses the BETR-D study and UV disinfecting combating VRE, MRSA,

C. difficile, and MDR acetin obacter. Dr. Anderson also discusses Antimicrobial Stewardship and Infection Prevention strategies.

Join us as Dr. Hudson Garrett discusses key points focused on the importance of an informed patient and ways to prevent healthcare associated infections. Dr. Garrett will also provide an in depth view of patients and the importance of collaborating with healthcare providers to reduce the risks of infections.

In a recent study published by the Journal of the American Medical Association, new data was released showing that at least 30 percent of all prescriptions written in doctors’ offices and emergency rooms are completely unnecessary. So how do we use these alarming results to transform the culture of overprescribing?

Dr. Katherine Fleming-Dutra, M.D., will:

Give a detailed explanation of the study results, and provide an in-depth review of specific findings;

Highlight what CDC is doing to promote antibiotic stewardship across healthcare settings, and

Identify what clinicians, other health care professionals, and patients can do to improve antibiotic prescribing, therefore fighting antibiotic resistance.

Listen in as our guest, Dr. Deverick J. Anderson, MD, Director, Duke Center for Antimicrobial Stewardship and Infection Prevention, Associate Professor of Medicine, Division of Infectious Diseases, discusses the BETR-D study and UV disinfecting combating VRE, MRSA,

C. difficile, and MDR acetin obacter. Dr. Anderson also discusses Antimicrobial Stewardship and Infection Prevention strategies.

This episode is focused on using antibiotics wisely and how YOU can help in the fight of antibiotic resistance.

Listen in as these two stellar Physicians discuss the topics of Clostridium difficile infections and Antibiotic usage. Important topics for citizens on a global level.

This episode will provide foundational educational information about the microbiome by answering the fundamental questions of what is it, why is it important, how does it impact patients with C. difficile infections, and what are the possibilities of the microbiome as a therapeutic target for future drugs. This interview will be with Dr. Matthew Henn, Senior Vice President and Head of Drug Discovery & Bioinformatics at Seres Therapeutics, Inc,. Seres Therapeutics is a leading microbiome therapeutics company dedicated to creating a new class of medicines to treat diseases resulting from imbalances in the microbiome. These first-in-class drugs, called Ecobiotics®, are ecological compositions of beneficial organisms that are designed to restore a healthy human microbiome. The discovery efforts at Seres Therapeutics currently span metabolic, inflammatory, and infectious diseases.

Join us as we discuss a promising and new treatment for a C. difficile infection. Summit Therapeutic's Ridinilazole, a microbiome preserving antibiotic will be introduced with updates by our two guests

Dr. Kevin W. Garey, Chair, Department of Pharmacy Practice and Translational Research, Professor of Pharmacy Practice at the University of Houston College of Pharmacy, Houston, Texas and

Dr. Richard Vickers, Chief Scientific Officer at Summit Therapeutics..

Join us as we discuss a promising and new treatment for a C. difficile infection. Summit Therapeutic's Ridinilazole, a microbiome preserving antibiotic will be introduced with updates by our two guests

Dr. Kevin W. Garey, Chair, Department of Pharmacy Practice and Translational Research, Professor of Pharmacy Practice at the University of Houston College of Pharmacy, Houston, Texas and

Dr. Richard Vickers, Chief Scientific Officer at Summit Therapeutics..

Join us as we discuss the protection of the natural gut microbiome from the unintended consequences of intravenous (IV) antibiotics which are excreted into the gut is expected to protect against opportunistic enteric infections. Recent clinical data suggest that the absence or abundance of certain microbes may be directly linked to certain infections and diseases, including Clostridium difficile infection (CDI) and irritable bowel syndrome (IBS). Synthetic Biologics is developing two microbiome-focused drug candidates in Phase 2 development including, SYN-004 which is designed to protect the gut microbiome by degrading certain IV beta-lactam antibiotics for the prevention of CDI, AAD and the emergence of antibiotic-resistant organisms, and SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C).